FibroGen Announces Positive Type C Meeting With The FDA For Roxadustat In Patients With Anemia Associated With Lower-Risk Myelodysplastic Syndromes
Refinitiv閱讀少於1分鐘
FibroGen Inc FGEN:
FIBROGEN ANNOUNCES POSITIVE TYPE C MEETING WITH THE FDA FOR ROXADUSTAT IN PATIENTS WITH ANEMIA ASSOCIATED WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES
登入或建立一個永久免費帳戶來閱讀此新聞